Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Expenditure on biosimilars in the United States in 2014, by type (in billion U.S. dollars)*

Exclusive Premium Statistic

U.S. spending on biosimilars by type 2014 This statistic displays the annual spending on biosimilars in the United States in 2014, by type. During this year, 8.6 billion U.S. dollars that were spent on insulins were to expire between 2015 and 2019. In 2009, the Biologics Price Competition and Innovation Act established a biosimilar pathway which has led to several applications and approvals.
Show more
Rest of classNon-originalsExpiry in 2015-19
----
----
----
----
----
Rest of classNon-originalsExpiry in 2015-19
----
----
----
----
----

Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1.5m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account


only $49 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

View price details

Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1.5m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account


only $49 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

View price details

Download Settings Share
Chart type
Datalabels
Share on Social Media
Download started
Please be patient - this may take a moment
Description Source More information
This statistic displays the annual spending on biosimilars in the United States in 2014, by type. During this year, 8.6 billion U.S. dollars that were spent on insulins were to expire between 2015 and 2019. In 2009, the Biologics Price Competition and Innovation Act established a biosimilar pathway which has led to several applications and approvals.
Show more
Release date
April 2015
Region
United States
Survey time period
2014
Supplementary notes
* Includes biological molecules in classes with current non-original biologics and upcomimg losses of exclusivity.
Open this statistic in...

More information

Statista Accounts: Access All Statistics. Starting from $588 / Year

Basic Account

Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account

Your perfect start with Statista

  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account

Full access

Corporate solution including all features.

Send request

* All products require an annual contract.
   Prices do not include sales tax
   (New York residents only).
Leading companies trust Statista:
I think of Statista as Google for researchers. Statista provides you with the information you search for right away.
Dr. Horst Stipp

Dr. Horst Stipp
EVP, Research & Innovation, Advertising Research Foundation

Statistics on "Pharmaceutical trends in Europe"

  • Overview
The most important statistics
  • European Pharmaceutical companies
The most important statistics
  • Self-medication market
The most important statistics
  • Employment
The most important statistics
  • Clinical Trials
The most important statistics
Need help with using Statista for your research? Tutorials and first steps

Further Content: Statistics, Studies, and Topic Pages

Statistics on the topic

Topics

About Statista

Learn more about how Statista can support your business.

Request webinar
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.

News